Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07573436 · ClinicalTrials.gov registry record · Phase 1
Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)
A Phase 1 study, sponsored by University of Utah.
- Not yet
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT07573436 is a Phase 1 study that has not yet begun recruiting, run by University of Utah. The registered enrollment target is 23 participants.
The verdict
NCT07573436, a Phase 1 study, has not yet begun recruiting, sponsored by University of Utah.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD). The purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine and rituximab are effective in participants with post-transplant lymphoproliferative disorders (PTLD).
Interventions
- DRUG Loncastuximab tesirine
- DRUG Rituximab or rituximab biosimilar
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2026-06 |
| Est. Completion | 2031-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07573436
The ClinicalTrials.gov registry entry for NCT07573436 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Loncastuximab tesirine is the first listed.
NCT07573436 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07573436 about?
NCT07573436 is a clinical study titled "Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO)". The purpose of phase I of this clinical trial is to learn the recommended dose of the drugs loncastuximab tesirine and rituximab in participants with post-transplant lymphoproliferative disorders (PTLD). The purpose of phase II of this clinical trial is to learn if the drugs loncastuximab tesirine ...
What is the current status of trial NCT07573436?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2026-06. Estimated completion is 2031-06.
What interventions are being tested in trial NCT07573436?
The interventions under investigation include: Loncastuximab tesirine (DRUG), Rituximab or rituximab biosimilar (DRUG).
Who is sponsoring clinical trial NCT07573436?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.